Emergent BioSolutions Inc.
NYSE•EBS
CEO: Mr. Richard S. Lindahl M.B.A.
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 2006-11-15
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
連絡先情報
400 Professional Drive, Suite 400, Gaithersburg, MD, 20879, United States
240-631-3200
時価総額
$429.61M
PER (TTM)
8.3
35.9
配当利回り
--
52週高値
$14.06
52週安値
$4.02
52週レンジ
順位53Top 76.1%
2.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$148.70M+0.00%
直近4四半期の推移
EPS
-$1.01+0.00%
直近4四半期の推移
フリーCF
$73.80M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Operating Income Rebounds Strongly Income from operations $100.1M versus $(108.7)M loss; Net income $52.6M versus $(190.6)M loss.
Gross Margin Percentage Improves Gross margin 45% versus 26%; driven by lower cost of sales $326.2M down 52% from prior year.
Cash Position Significantly Strengthened Total cash $209.1M, nearly doubling to 98% increase; Total borrowings reduced 14% to $572.1M.
Key Milestone Payments Received Recognized $50.0M incremental income from travel health business milestone payments received in 2025.
リスク要因
USG Funding Dependency Risk Substantial revenue derived from USG procurement contracts; reduction or discontinuation harms financial condition materially.
Manufacturing Compliance Challenges Inability to maintain quality and compliance at facilities impedes manufacturing and delivery of critical products.
Product Competition Intensifies NARCAN faces generic/branded competition eroding sales; biosimilar entry threatens CYFENDUS, BioThrax, and ACAM2000.
Litigation and Investigation Exposure Ongoing government investigations and legal proceedings may result in fines, sanctions, or reputational harm.
見通し
2026 Sustainable Growth Focus Plans emphasize disciplined execution, improved operating performance, and long-term sustainable growth mission execution.
Capital Allocation Discipline Continued focus on disciplined capital allocation strategy; reauthorized $50.0M share repurchase program through March 2027.
Reinforce Quality Standards Priorities include reinforcing highest standards of patient safety, quality, and compliance across all operations.
Strategic Partnership Advancement Advancing strategic partnerships and targeted innovation aligned with core capabilities for future preparedness needs.
同業比較
売上高 (TTM)
$742.90M
$680.39M
$563.94M
粗利益率 (最新四半期)
100.0%
91.5%
83.5%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| ALMS | $2.75B | -11.2 | -75.5% | 7.7% |
| CRVS | $1.42B | -92.9 | -25.8% | 1.3% |
| OLMA | $1.23B | -8.9 | -41.5% | 1.3% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-12.5%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年5月5日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし